1AE:F:F-Argen-X (EUR)

COMMON STOCK | Biotechnology |

Last Closing

USD 468.4

Change

0.00 (0.00)%

Market Cap

USD 28.01B

Volume

7.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-08-04 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NOV:F Novo Nordisk A/S

N/A

USD 526.04B
NOVA:F Novo Nordisk A/S

N/A

USD 524.27B
RGO:F Regeneron Pharmaceuticals Inc

N/A

USD 117.89B
CSJA:F CSL LTD SPON.ADR 2

N/A

USD 91.04B
CSJ:F CSL Limited

N/A

USD 91.04B
UNC0:F UCB S.A. UNSP.ADR 1/2

N/A

USD 31.06B
DUL:F Alnylam Pharmaceuticals Inc

N/A

USD 30.44B
1AEA:F argenx SE

N/A

USD 29.18B
0QF:F Moderna Inc

N/A

USD 25.22B
22UA:F BioNTech SE

N/A

USD 19.33B

ETFs Containing 1AE:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 35.93% 78% C+ 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 35.93% 78% C+ 82% B
Trailing 12 Months  
Capital Gain 5.40% 66% D+ 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.40% 65% D 51% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 14.07% 80% B- 78% C+
Dividend Return 14.07% 80% B- 72% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 16.84% 87% B+ 70% C-
Risk Adjusted Return 83.57% 99% N/A 93% A
Market Capitalization 28.01B 99% N/A 93% A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector